Hovione's drug delivery tech lands eye disease licensing deal

Hovione’s drug delivery strategy has delivered a win, with Ji Xing Pharmaceuticals picking up the global license for the preclinical eye disease program JX08.

Product development at Hovione is focused on two areas: The use of drug delivery platforms to improve or reposition existing molecules and the development of generic dry-powder inhalers. The strategy has spawned JX08, a preclinical ophthalmology prospect Shanghai-based Ji Xing has bagged in a global license agreement.